Publication Name	World Journal of Gastroenterology
Manuscript ID	36534
Country	Japan

Received	2017-10-04 19:58
Peer-Review Started	2017-10-05 14:31
To Make the First Decision	2017-10-25 01:06
Return for Revision	2017-10-25 08:53
Revised	2017-10-30 05:06
Second Decision	2017-11-14 06:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-11-14 18:55
Articles in Press	2017-11-14 18:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-12-07 00:58
Publish the Manuscript Online	2017-12-20 02:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Control Study
Article Title	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
Manuscript Source	Unsolicited Manuscript
All Author List	Kosuke Kaji, Hiroaki Takaya, Soichiro Saikawa, Masanori Furukawa, Shinya Sato, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro and Hitoshi Yoshiji
ORCID	Author(s) ORCID Number Kosuke Kaji http://orcid.org/orcid.org/0000-0002-1822-6759 Hiroaki Takaya http://orcid.org/orcid.org/0000-0002-4990-7573 Soichiro Saikawa http://orcid.org/0000-0002-3440-050X Masanori Furukawa http://orcid.org/orcid.org/0000-0002-9317-9083 Shinya Sato http://orcid.org/orcid.org/0000-0003-3049-3443 Hideto Kawaratani http://orcid.org/0000-0002-4361-0592 Mitsuteru Kitade http://orcid.org/0000-0001-7592-7589 Kei Moriya http://orcid.org/0000-0002-2878-8296 Tadashi Namisaki http://orcid.org/orcid.org/0000-0002-3158-5318 Takemi Akahane http://orcid.org/orcid.org/0000-0002-6675-0475 Akira Mitoro http://orcid.org/orcid.org/0000-0002-6666-5633 Hitoshi Yoshiji http://orcid.org/orcid.org/0000-0002-5243-8544
Funding Agency and Grant Number
Corresponding Author	Kosuke Kaji, MD, PhD, Assistant Professor, Doctor, Doctor, Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 6348522, Japan. kajik@naramed-u.ac.jp
Key Words	Gut microbiome; Hepatic encephalopathy; Liver cirrhosis; Endotoxin; Rifaximin
Core Tip	Hepatic encephalopathy (HE) is characterized by deficits in cognitive, psychiatric, and motor function and ranges in severity from minimal to overt HE and coma. Rifaximin is used for standard treatment of HE, targeting reduction of ammonia and gut bacterial translocation. This study demonstrates that rifaximin improves hyperammonemia and cognitive impairment with the linkage of decreased endotoxin activity in patients with decompensated cirrhosis. The diversity and major components of gut microbiome analyzed by 16S rRNA gene sequencing are not altered by treatment with rifaximin. This is the first report of systemic and local effects of rifaximin in Japanese patients.
Publish Date	2017-12-20 02:49
Citation	Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366
URL	http://www.wjgnet.com/1007-9327/full/v23/i47/8355.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i47.8355

Full Article (PDF)	WJG-23-8355.pdf
Full Article (Word)	WJG-23-8355.doc
Manuscript File	36534-Review.docx
Answering Reviewers	36534-Answering reviewers.pdf
Audio Core Tip	36534-Audio core tip.mp3
Biostatistics Review Certificate	36534-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	36534-Conflict-of-interest statement.pdf
Copyright License Agreement	36534-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	36534-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	36534-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	36534-Language certificate.pdf
Supplementary Material	36534-Supplementary material.pdf
Peer-review Report	36534-Peer-review(s).pdf
Scientific Misconduct Check	36534-Scientific misconduct check.pdf
Scientific Editor Work List	36534-Scientific editor work list.pdf